This page was exported from Dr Thomas Challenger [ ]
Export date: Tue Jan 16 13:47:15 2018 / +0000 GMT

PCSK9 Inhibitors

PCSK9 inhibitors: a major advance in cholesterol-lowering drug therapy

Gregory Curfman, MD, Editor in Chief, Harvard Health Publications

Every so often a medical advance comes along that rewrites the script for treating a disease or condition. After today's announcements of impressive results of a new type of cholesterol-lowering drug, that scenario just might happen in the next few years.

The new drugs, called PCSK9 inhibitors, are monoclonal antibodies. They target and inactivate a specific protein in the liver. Knocking out this protein, called proprotein convertase subtilisin kexin 9, dramatically reduces the amount of harmful LDL cholesterol circulating in the bloodstream. Lower LDL translates into healthier arteries and fewer heart attacks, strokes, and other problems related to cholesterol-clogged arteries.



Post date: 2015-04-25 14:31:16
Post date GMT: 2015-04-25 04:31:16
Post modified date: 2016-04-20 13:09:59
Post modified date GMT: 2016-04-20 03:09:59

Powered by [ Universal Post Manager ] plugin. MS Word saving format developed by gVectors Team